Fisher & Paykel Healthcare Corporation Limited (FSPKF) Research

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, specializes in the global development, manufacturing, marketing, and distribution of sophisticated medical device products and systems. The company's offerings are crucial for acute and chronic respiratory care, surgical support, and the management of obstructive sleep apnea (OSA) in both clinical and home environments. Its product portfolio features advanced solutions such as the Airvo 2 humidified high-flow nasal system, Optiflow nasal high-flow therapy, and the F&P 850 System for both non-invasive and invasive ventilation. Additionally, Fisher & Paykel Healthcare provides specialized infant respiratory products, encompassing resuscitation devices, continuous positive airway pressure (CPAP) therapy, and nasal high-flow therapy solutions for pediatric patients. The company further supplies a comprehensive range of hospital-grade items, including humidification units, breathing circuits, chambers, masks, nasal cannulas, surgical components, and various interfaces and accessories. For homecare, it offers a diverse collection of masks, CPAP machines, software for data management, humidifiers, and other related accessories. Established in 1934, Fisher & Paykel Healthcare Corporation Limited maintains its headquarters in Auckland, New Zealand.

Open Fisher & Paykel Healthcare Corporation Limited (FSPKF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.